To evaluate the effectiveness of cemiplimab, a Programmed-cell-death-1(PD-1) protein inhibitor, for the treatment of cutaneous periocular-locally-advanced squamous-cell-carcinoma (POLA-SCC) with orbital-invasion.
Multicentre real-world retrospective study. Demographic and clinical data were collected and analysed for patients with biopsy-proven POLA-SCC(AJCC-T4) with orbital-invasion who were treated with cemiplimab at one of four tertiary medical centres in 2019–2022.
The cohort included 13 patients, 8 males and 5 females, of median age 76 years (IQR65–86). The median duration of treatment was 5.0months (IQR3.5–10.5) and the median follow-up time, 15.0 months (IQR10.5–30). The overall response rate was 69.2%. Complete response was documented in seven patients (53.8%), partial response in two (15.4%), stable disease in one (7.7%), and progressive disease in two (15.4%); in one patient (7.7%), response was not evaluable. Six complete responders (46.1% of the cohort) received no further treatment and did not have a recurrence during an average follow-up of 6.14 (±6.9) months from treatment cessation. None of the patients underwent orbital-exenteration. The majority of adverse events were mild (grade-1), except for a moderate increase in creatinine level (grade-2), severe bullous dermatitis (grade-3), and myocarditis (grade-5) in one patient each. Four patients (30.7%) died during the follow-up period, all of whom had an Eastern-Cooperative-Oncology-Group score of 4 at presentation.
To our knowledge, this is the largest study to date on cemiplimab therapy for cutaneous POLA-SCC with orbital-invasion. Treatment was shown to be effective, with an overall response rate of 69.2%. Cemiplimab holds promise for the treatment of patients with tumours invading the orbit as it may alleviate the need for orbital exenteration.
This is a preview of subscription content, access via your institution
Subscribe to this journal
Receive 18 print issues and online access
$259.00 per year
only $14.39 per issue
Rent or buy this article
Get just this article for as long as you need it
Prices may be subject to local taxes which are calculated during checkout
Reifler DM, Hornblass A. Squamous cell carcinoma of the eyelid. Surv Ophthalmol. 1986;30:349–65.
Donaldson MJ, Sullivan TJ, Whitehead KJ, Williamson RM. Squamous cell carcinoma of the eyelids. Br J Ophthalmol. 2002;86:1161–5.
Nemet AY, Deckel Y, Martin PA, Kourt G, Chilov M, Sharma V, et al. Management of periocular basal and squamous cell carcinoma: a series of 485 cases. Am J Ophthalmol. 2006;142:293–7.
Nasser QJ, Roth KG, Warneke CL, Yin VT, El Sawy T, Esmaeli B. Impact of AJCC ‘T’ designation on risk of regional lymph node metastasis in patients with squamous carcinoma of the eyelid. Br J Ophthalmol. 2014;98:498–501.
Sun MT, Andrew NH, O’Donnell B, McNab A, Huilgol SC, Selva D. Periocular squamous cell carcinoma: TNM staging and recurrence. Ophthalmology. 2015;122:1512–6.
Goldfarb JA, Ferrarotto R, Gross N, Goepfert R, Debnam JM, Gunn B, et al. Immune checkpoint inhibitors for treatment of periorbital squamous cell carcinoma. Br J Ophthalmol. 2021; https://doi.org/10.1136/bjophthalmol-2021-319417.
Malhotra R, Huilgol SC, Huynh NT, Selva D. The Australian Mohs database: periocular squamous cell carcinoma. Ophthalmology. 2004;111:617–23.
Faustina M, Diba R, Ahmadi MA, Esmaeli B. Patterns of regional and distant metastasis in patients with eyelid and periocular squamous cell carcinoma. Ophthalmology. 2004;111:1930–2.
Ridenhour CE, Spratt JS Jr. Epidermoid carcinoma of the skin involving the parotid gland. Am J Surg. 1966;112:504–7.
Sullivan TJ. Squamous cell carcinoma of eyelid, periocular, and periorbital skin. Int Ophthalmol Clin. 2009;49:17–24.
McCord CD Jr, Cavanagh HD. Microscopic features and biologic behavior of eyelid tumors. Ophthalmic Surg. 1980;11:671–81.
Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol. 1992;26:976–90.
Yin VT, Pfeiffer ML, Esmaeli B. Targeted therapy for orbital and periocular basal cell carcinoma and squamous cell carcinoma. Ophthalmic Plast Reconstr Surg. 2013;29:87–92.
Xu S, Sagiv O, Rubin ML, Sa HS, Tetzlaff MT, Nagarajan P, et al. Validation study of the AJCC cancer staging manual, eighth edition, staging system for eyelid and periocular squamous cell carcinoma. JAMA Ophthalmol. 2019;137:537–42.
Lazarevic D, Ramelyte E, Dummer R, Imhof L. Radiotherapy in periocular cutaneous malignancies: a retrospective study. Dermatology. 2019;235:234–9.
Fitzpatrick PJ, Thompson GA, Easterbrook WM, Gallie BL, Payne DG. Basal and squamous cell carcinoma of the eyelids and their treatment by radiotherapy. Int J Radiat Oncol Biol Phys. 1984;10:449–54.
Gerring RC, Ott CT, Curry JM, Sargi ZB, Wester ST. Orbital exenteration for advanced periorbital non-melanoma skin cancer: prognostic factors and survival. Eye. 2017;31:379–88.
Rasmussen ML, Ekholm O, Prause JU, Toft PB. Quality of life of eye amputated patients. Acta Ophthalmol. 2012;90:435–40.
Ye J, Lou L, Jin K, Xu Y, Ye X, Moss T, et al. Vision-related quality of life and appearance concerns are associated with anxiety and depression after eye enucleation: a cross-sectional study. PLoS One. 2015;10:e0136460.
Baum SH, Pfortner R, Manthey A, Bechrakis NE, Mohr C. Periorbital, conjunctival and primary intraorbital carcinomas: Survival and risk factors after orbital exenteration. Eye. 2021;35:1365–76.
Martel A, Baillif S, Nahon-Esteve S, Gastaud L, Bertolotto C, Lassalle S, et al. Orbital exenteration: an updated review with perspectives. Surv Ophthalmol. 2021;66:856–76.
Kiratli H, Koc I. Orbital exenteration: Institutional review of evolving trends in indications and rehabilitation techniques. Orbit. 2018;37:179–86.
Markham A, Duggan S. Cemiplimab: first global approval. Drugs. 2018;78:1841–6.
Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, et al. PD-1 blockade with cemiplimab in advanced cutaneous squamous-cell carcinoma. N. Engl J Med. 2018;379:341–51.
Schaffer M, Simonovich A, I O, Batash R, Asna N. Use of cemiplimab in locally advanced cutaneous squamous cell carcinoma. J Clin Case Rep. 2020;10:1320.
Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, et al. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020;21:294–305.
Nageli M, Mangana J, Chaloupka K, Dummer R. Cutaneous SCC with orbital invasion: case series. J Eur Acad Dermatol Venereol. 2022;36:59–62.
McLean LS, Lim AM, Webb A, Cavanagh K, Thai A, Magarey M, et al. Immunotherapy to avoid orbital exenteration in patients with cutaneous squamous cell carcinoma. Front Oncol. 2021;11:796197.
Steren B, Burtness B, Bhatia A, Demirci H, Shinder R, Yoo D, et al. Cemiplimab for orbital squamous cell carcinoma in 11 cases. Ophthalmic Plast Reconstr Surg. 2022;38:496–502.
Strippoli S, Fanizzi A, Quaresmini D, Nardone A, Armenio A, Figliuolo F, et al. Cemiplimab in an elderly frail population of patients with locally advanced or metastatic cutaneous squamous cell carcinoma: a single-center real-life experience from Italy. Front Oncol. 2021;11:686308.
Salzmann M, Leiter U, Loquai C, Zimmer L, Ugurel S, Gutzmer R, et al. Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study. Eur J Cancer. 2020;138:125–32.
Hanna GJ, Ruiz ES, LeBoeuf NR, Thakuria M, Schmults CD, Decaprio JA, et al. Real-world outcomes treating patients with advanced cutaneous squamous cell carcinoma with immune checkpoint inhibitors (CPI). Br J Cancer. 2020;123:1535–42.
In GK, Vaidya P, Filkins A, Hermel DJ, King KG, Ragab O, et al. PD-1 inhibition therapy for advanced cutaneous squamous cell carcinoma: a retrospective analysis from the University of Southern California. J Cancer Res Clin Oncol. 2021;147:1803–11.
Hober C, Fredeau L, Pham-Ledard A, Boubaya M, Herms F, Celerier P, et al. Cemiplimab for locally advanced and metastatic cutaneous squamous-cell carcinomas: real-life experience from the French CAREPI Study Group. Cancers 2021;13:3547.
Ben Ishai M, Tiosano A, Fenig E, Ben Simon G, Yassur I. Outcomes of vismodegib for periocular locally advanced basal cell carcinoma from an open-label trial. JAMA Ophthalmol. 2020;138:749–55.
Eiger-Moscovich M, Reich E, Tauber G, Berliner O, Priel A, Ben Simon G, et al. Efficacy of vismodegib for the treatment of orbital and advanced periocular basal cell carcinoma. Am J Ophthalmol. 2019;207:62–70.
Gershoni A, Tiosano A, Ben Ishai M, Barayev E, G JBS, Yassur I. Vismodegib improves quality of life in patients with periocular locally advanced basal cell carcinoma: subgroup analysis, STEVIE trial. Eye. 2022;36:407–13.
Kahana A, Unsworth SP, Andrews CA, Chan MP, Bresler SC, Bichakjian CK, et al. Vismodegib for preservation of visual function in patients with advanced periocular basal cell carcinoma: The VISORB Trial. Oncologist. 2021;26:e1240–e1249.
Wang DY, Salem JE, Cohen JV, Chandra S, Menzer C, Ye F, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4:1721–8.
Guillaume T, Puzenat E, Popescu D, Aubin F, Nardin C. Cemiplimab-rwlc in advanced cutaneous squamous cell carcinoma: real-world experience in a French dermatology department. Br J Dermatol. 2021;185:1056–8.
Valentin J, Gerard E, Ferte T, Prey S, Dousset L, Dutriaux C, et al. Real-world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma. J Geriatr Oncol. 2021;12:1110–3.
Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, et al. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021;9:e002757.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tiosano, A., Ben-Ishai, M., Cnaany, Y. et al. Primary cemiplimab treatment for orbital squamous cell carcinoma is effective and may alleviate the need for orbital exenteration. Eye (2023). https://doi.org/10.1038/s41433-022-02358-y